 |
|
|
|
|
|
 Title: |
US5514774:
Conotoxin peptides
[ Derwent Title ]
|
| Country: |
US United States of America
|
| |
| Inventor: |
Olivera, Baldomero M.; Salt Lake City, UT
Cruz, Lourdes J.; Salt Lake City, UT
Hillyard, David R.; Salt Lake City, UT
McIntosh, J. Michael; Salt Lake City, UT
Santos, Ameurfina D.; Diliman, Philippines
|
| Assignee: |
University of Utah Research Foundation, Salt Lake City, UT
other patents from UNIVERSITY OF UTAH RESEARCH FOUNDATION (600050) (approx. 286)
News, Profiles, Stocks and More about this company
|
| Published / Filed: |
1996-05-07
/ 1993-10-19
|
| Application Number: |
US1993000137800
|
| IPC Code: |
Advanced:
C07K 14/435;
C12N 15/12;
A61K 38/00;
A61K 39/00;
Core:
more...
IPC-7:
A61K 38/04;
C07K 7/00;
C07K 14/435;
|
| ECLA Code: |
C07K14/435;
|
| U.S. Class: |
Current:
530/324;
530/325;
530/326;
530/327;
Original:
530/324;
530/325;
530/326;
530/327;
|
| Field of Search: |
530/324-326,327
514/012,13,14
|
| Government Interest: |
This invention was made with Government support under Grant No. GM-22737 awarded by the National Institutes of Health, Bethesda, Md. The United States Government has certain rights in the invention.
|
| Priority Number: |
| 1993-10-19 |
US1993000137800 |
|
| Abstract: |
The invention is directed to A-lineage conotoxin peptides, which are conotoxin peptides that have strong homology in the signal sequence and the 3'-untranslated region of the genes coding for these peptides to the sequences in the α-conotoxin peptides. The A-lineage conotoxin peptides include the α-conotoxin peptides, the α-conotoxin-like peptides and the .kappa.-conotoxin peptides, described further below. The α-conotoxin-peptides generally share a "core" sequence motif. This core sequence is termed the α3/5 core and is represented as Cys-Cys-Xaa-Xaa-Xaa-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Cys (SEQ ID NO:1). The α-conotoxin-like peptides generally share a core sequence termed the α4/7 core and is represented as Cys-Cys-Xaa-Xaa-Xaa-Xaa-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Cys (SEQ ID NO:2). The .kappa.-conotoxin peptides generally have a core sequence termed the .kappa.7/2/1/3 core and is represented as Cys-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Cys-Xaa-Xaa-Cys-Xaa-Cys-Xaa-Xaa-Xaa-Cys (SEQ ID NO:3).
|
| Attorney, Agent or Firm: |
Venable, Baetjer, Howard & Civiletti ;
|
| Primary / Asst. Examiners: |
Wax, Robert A.; Bugaisky, G. E.
|
| INPADOC Legal Status: |
Show legal status actions
Family Legal Status Report
|
|
|
|
|
|
|
| Parent Case: |
CROSS REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part of application Ser. No. 08/084,848, filed Jun. 29, 1993, now U.S. Pat. No. 5,432,155 which is incorporated herein by reference.
|
| Designated Country: |
BE CH FR GB GR IE IT LI LU MC NL SE KR
|
| Family: |
Show 51 known family members
|
First Claim:
Show all 3 claims |
What is claimed is:
1. A substantially pure A-lineage conotoxin peptide selected from the group consisting of:
- Gly-Cys-Cys-Cys-Asn-Pro-Ala-Cys-Gly-Pro-Asn-Tyr-Gly-Cys-Gly-Thr-Ser-Cys-Ser-Xaa1 (SEQ ID NO: 10), wherein Xaa1 is des-Xaa1 or Arg-Thr-Leu;
- (Gly-Cys-Cys-Ser-Asp-Pro-Arg-Cys-Ala-Trp-Arg-Cys (SEQ ID NO: 12);
- Arg-Asp- Xaa1 -Cys-Cys-Tyr-His-Pro-Thr-Cys-Asn-Met-Ser-Asn-Pro-Gln-Ile-Cys (SEQ ID NO: 13), wherein Xaa1 is Pro or hydroxy-Pro;
- Gly-Cys-Cys-Ser-His-Xaa1 -Ala-Cys-Ser-Val-Asn-Asn-Xaa2 -Xaa3 -Ile-Cys (SEQ ID NO: 14), wherein Xaa1 or Xaa2 is Pro or hydroxy-Pro, and Xaa3 is Asp or β-carboxyaspartate;
- Glu-Cys-Cys-Thr-His-Xaa1 -Ala-Cys-His-Val-Ser-His-Xaa2 -Glu-Leu-Cys (SEQ ID NO: 15), wherein Xaa1 or Xaa2 is Pro or hydroxy-Pro;
- Asp-Tyr-Cys-Cys-His-Arg-Gly-Pro-Cys-Met-Val-Trp-Cys (SEQ ID NO: 16);
- Gln-Asn-Cys-Cys-Ser-Ile-Pro-Ser-Cys-Trp-Glu-Lys-Tyr-Lys-Cys-Xaa1 (SEQ ID NO: 17), wherein Xaa1 is Ser or Asn;
- Gly-Cys-Cys-Ala-Ile-Arg-Glu-Cys-Arg-Leu-Gln-Asn-Ala-Ala-Tyr-Cys-Gly-Gly-Ile-Tyr (SEQ ID NO: 18);
- Gly-Cys-Cys-Ser-Asn-Xaa1 -Val-Cys-His-Leu-Glu-His-Ser-Asn-Leu-Cys (SEQ ID NO: 19), wherein Xaa1 is Pro or hydroxy-Pro;
- Gly-Gly-Cys-Cys-Ser-Phe-Xaa1 -Ala-Cys-Arg-Lys-Tyr-Arg-Xaa2 -Xaa3 -Met-Cys-Gly (SEQ ID NO:20), wherein Xaa1 or Xaa2 is Pro or hydroxy-Pro, and Xaa3 is Glu or γ-carboxyglutmate:
- Ala-Cys-Cys-Ser-Tyr-Xaa1 -Pro-Cys-Asn-Val-Asn-Tyr-Xaa2 -Xaa3 -Ile-Cys-Gly-Gly-Arg (SEQ ID NO:21), wherein Xaa1 or Xaa2 is Pro or hydroxy-Pro, and Xaa3 is Glu or γ-carboxyglutamate;
- Asn-Gly-Cys-Cys-Arg-Asn-Pro-Ala-Cys-Glu-Ser-His-Arg-Cys-Gly (SEQ ID NO:22);
- Asn-Val-Val-Val-Thr-Ser-Phe-Glu-Pro-Thr-Thr-Leu-Ala-Pro-Val-Pro-Ser-Asp- Cys-Cys-Gln-Val-Ser-Ser-Cys-Trp-Asn-Leu-Tyr-Gly-Leu-Glu-Cys-Thr-Gly-Ile-Thr-Arg- Arg-Arg-Thr-Leu (SEQ ID NO:23);
- Asn-Val-Ala-Ile-Thr-Ser-Phe-Glu-Pro-Thr-Thr-Leu-Ala-Pro-Val-Pro-Ser-Asp- Cys-Cys-Gln-Val-Ser-Ser-Cys-Trp-Asn-Leu-Tyr-Gly-Pro-Glu-Cys-Thr-Gly-Ile-Thr-Arg-Arg-Arg-Thr-Leu (SEQ ID NO:24);
- Arg-Asp-Xaa1 -Cys-Cys-Tyr-His-Pro-Thr-Cys-Asn-Met-Ser-Asn-Pro-Gln-Ile-Cys (SEQ ID NO:31), wherein Xaa1 is Pro or hydroxy-Pro and;
- Arg-Asp-Xaa1 -Cys-Cys-Ser-Asn-Pro-Ala-Cys-Asn-Val-Asn-Asn-Pro-Gln-Ile-Cys (SEQ ID NO: 32), wherein Xaa1 is Pro or hydroxy-Pro.
|
| Background / Summary: |
Show background / summary
|
| Drawing Descriptions: |
Show drawing descriptions
|
| Description: |
Show description
|
| Forward References: |
Show 19 U.S. patent(s) that reference this one
|
|
